Pep-Therapy
Developing first-in-class peptides as targeted therapies in oncology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 Valuation: €0.0 -15.8x EV/EBITDA | round | |
€1.0m | Debt | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (92212 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (1389 %) | - | (65232 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Pep-Therapy is a clinical-stage biotechnology company established in 2014 as a spin-off from Sorbonne University and the Institut Curie. The company was co-founded by Antoine Prestat, who now serves as the CEO.
Pep-Therapy focuses on the development of first-in-class peptides for targeted therapies in oncology. The company's approach is based on its proprietary Cell Penetrating and Interfering Peptides (CP&IP) technology. This technology is designed to create peptides that can penetrate cells and interfere with key mechanisms in cancer cells, aiming to offer new treatment options for serious diseases with high medical needs.
The lead product, PEP-010, is a therapeutic peptide that acts as a pro-apoptotic agent, meaning it is designed to induce programmed cell death specifically in tumor cells. This targeted approach seeks to minimize damage to healthy cells, a common challenge in cancer treatment.
Pep-Therapy operates on a B2B business model, seeking collaborations and partnerships with pharmaceutical and biotech companies to advance its research and bring its therapies to market. The company is focused on the oncology market and is currently in the clinical stage of development for its lead product.
Keywords: biotechnology, oncology, peptides, targeted therapy, clinical-stage, cell penetrating peptides, pro-apoptotic, cancer treatment, therapeutic peptides, CP&IP technology